ALGS - The Phase 1b study by Aligos Therapeutics to assess its Class II Capsid Assembly modulator ALG-000184 started with a 12-week dosing cohort.
The clinical-stage biopharmaceutical company Aligos Therapeutics, Inc. (Nasdaq:ALGS), which focuses on creating novel treatments for unmet medical needs in viral and liver diseases, announced today that enrollment in a 12-week dosing cohort of HBeAg-positive chronic hepatitis dB (CHB) subjects has started in the ongoing Phase 1b study ALG-000184-201 (NCT04536337). Lawrence Blatt, Ph.D., MBA, CEO, and Chairman of the Board at Aligos(Nasdaq: ALGS), said “This is a critical next step in our consideration of ALG-000184 as a chronic suppressive therapy and/or component of a functional cure regimen in patients with CHB.”
In both HBeAg-negative and -positive CHB ...
Get early insight on hidden secret gems on MicroSmallCap . Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here .
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer .
For further details see:
The Phase 1b study by Aligos Therapeutics to assess its Class II Capsid Assembly modulator, ALG-000184, started with a 12-week dosing cohort.